Lycia Therapeutics
Lycia Therapeutics aims to eliminate the source of disease by leveraging a novel platform of extracellular protein degradation, specifically through LYTAC degraders. Their mission is to improve patients' lives by creating therapeutics that target and eliminate disease drivers, with an initial focus on autoimmune and inflammatory diseases. The company develops modular, customizable therapeutics capable of addressing a broad spectrum of diseases, including some previously considered undruggable. Their innovative technology has the potential to make a life-changing impact on patients in urgent need of new options.
Industries
Nr. of Employees
small (1-50)
Lycia Therapeutics
Products
LCA-0061
Preclinical therapeutic program designed to bind and eliminate circulating IgE using a catalytic lysosomal-targeting degrader; single-dose non-human primate data reported to show rapid and near-complete reduction of total and free IgE. Phase 1 clinical study planned to evaluate safety, tolerability, and biomarker effects.
LCA-0321
Program engineered to bind and eliminate disease-causing thyroid-stimulating hormone receptor (TSHR) autoantibodies using a lysosomal-targeting degrader; preclinical data in mice and human cells reported to show rapid and selective elimination of patient-derived autoantibodies. Phase 1 clinical study planned to assess safety, tolerability, and biomarker impact.
LCA-0391
Program targeting MuSK-specific autoantibodies for MuSK+ myasthenia gravis using a lysosomal-targeting degrader; described as a development candidate in the public pipeline.
Antigen-specific autoantibody degrader programs (multiple)
Multiple discovery-stage programs to create degrader therapeutics that selectively remove antigen-specific autoantibodies for autoimmune disease indications.
Undisclosed inflammatory disease degrader programs
Multiple discovery-stage programs using catalytic lysosomal-targeting degrader approaches aimed at inflammatory disease indications; details not disclosed publicly.
Multi-target collaboration programs (external partnership)
Collaborative discovery and development programs with external pharmaceutical partners to apply the degrader platform to multiple targets in areas including immunology and pain.
LCA-0061
Preclinical therapeutic program designed to bind and eliminate circulating IgE using a catalytic lysosomal-targeting degrader; single-dose non-human primate data reported to show rapid and near-complete reduction of total and free IgE. Phase 1 clinical study planned to evaluate safety, tolerability, and biomarker effects.
LCA-0321
Program engineered to bind and eliminate disease-causing thyroid-stimulating hormone receptor (TSHR) autoantibodies using a lysosomal-targeting degrader; preclinical data in mice and human cells reported to show rapid and selective elimination of patient-derived autoantibodies. Phase 1 clinical study planned to assess safety, tolerability, and biomarker impact.
LCA-0391
Program targeting MuSK-specific autoantibodies for MuSK+ myasthenia gravis using a lysosomal-targeting degrader; described as a development candidate in the public pipeline.
Antigen-specific autoantibody degrader programs (multiple)
Multiple discovery-stage programs to create degrader therapeutics that selectively remove antigen-specific autoantibodies for autoimmune disease indications.
Undisclosed inflammatory disease degrader programs
Multiple discovery-stage programs using catalytic lysosomal-targeting degrader approaches aimed at inflammatory disease indications; details not disclosed publicly.
Multi-target collaboration programs (external partnership)
Collaborative discovery and development programs with external pharmaceutical partners to apply the degrader platform to multiple targets in areas including immunology and pain.
Expertise Areas
- Extracellular protein degradation therapeutics
- Antibody and biologics engineering
- Autoantibody-targeted therapeutics
- Preclinical in vivo pharmacology (rodent and non-human primate)
Key Technologies
- Lysosomal targeting chimeras for extracellular protein degradation
- Catalytic protein degrader constructs
- Antibody-based degrader platforms
- In vivo disease models (mouse, non-human primate)